Clinical Psychopharmacology and Neuroscience 2013 Apr; 11(1): 1-6
Long-acting Injectable Antipsychotics in First-episode Schizophrenia
Hyun-Ghang Jeong1,2, Moon-Soo Lee1,2
1Department of Psychiatry, Korea University Guro Hospital, 2Research Institute of Mental Health, Korea University College of Medicine, Seoul, Korea
Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.
Clinical Psychopharmacology and Neuroscience 2013 Apr; 11(1): 1-6
Keyword : Antipsychotic agents; Injections; Schizophrenia; Delayed-action preparations.
   
2010 © Copyright The Korean College of Neuropsychopharmacology. All Rights Reserved.
Rm 1003 Life Officetel Bldg., Yeouido-dong, Yeongdeungpo-gu, Seoul, KOREA
Tel) +82-2-784-2742   Fax) +82-2-784-5542   E-mail) secretariat@kcnp.or.kr   Powered by INFOrang.co., Ltd